Company / SG&A per Share
Sarepta Therapeutics SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$5.07
FY2025
5-year range
$3.56 / $5.95
FY2021-FY2025
Trend
-14.7%
vs FY2024
Sector context
#34 of 210
Health Care
What the data says
Sarepta Therapeutics's sg&a per share of $5.07 is higher than 84% of companies in the Health Care sector (FY2025). SG&A per Share has fluctuated over the past 10 years, ranging from $1.73 in FY2019 to $5.95 in FY2024.
Based on SEC 10-K filings.
5.07 in FY2025 with a 5-year CAGR of +12.9%. Top quartile in the Health Care sector.
Improved from $5.48 to $5.07 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +11.6%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 210This company $5.07 Sector average $40.75
▼
-87.5% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 14.7% year-over-year.
- Ranks #34 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2024.
- Lowest sg&a per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.07 | -14.7% |
| FY2024 | $5.95 | +8.6% |
| FY2023 | $5.48 | +50.2% |
| FY2022 | $3.65 | +2.5% |
| FY2021 | $3.56 | +28.9% |
| FY2020 | $2.76 | +60.1% |
| FY2019 | $1.73 | -46.2% |
| FY2018 | $3.21 | +43.1% |
| FY2017 | $2.24 | +22.1% |
| FY2016 | $1.84 | +3.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026